Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Regeneron | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Regeneron

U.S. EYLEA Injection sales increased 9% to $1.1 billion

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron
1Q Revenues: $1.7 billion (+13%)
1Q Earnings: $461.1 million (-4%)
Comments: EYLEA Injection U.S. sales increased 9% to $1.1 billion. EYLEA sales outside the U.S., recorded by the company’s collaborator Bayer, increased 7% to $669 million. Global Dupixent sales, which are recorded by the company’s collaborator Sanofi, were $374 million. Libtayo U.S. sales were $27 million in the quarter; Libtayo was launched in October 2018.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters